News
UCBJY
151.18
-0.62%
-0.95
ValuEngine Weekly Market Commentary
Seeking Alpha · 7h ago
Jefferies Reaffirms Their Hold Rating on UCB SA (0NZT)
TipRanks · 23h ago
Weekly Report: what happened at UCBJY last week (1019-1023)?
Weekly Report · 1d ago
UCB SA (0NZT) Gets a Buy from TD Cowen
TipRanks · 1d ago
What's Going On with MoonLake Immunotherapeutics Stock on Thursday?
Benzinga · 4d ago
Weekly Report: what happened at UCBJY last week (1012-1016)?
Weekly Report · 10/19 10:27
UCB Scores FDA Win With First-Of-Its-Kind Daily Autoinjector for Rare Muscle Disorder
Benzinga · 10/16 14:53
Weekly Report: what happened at UCBJY last week (1005-1009)?
Weekly Report · 10/12 10:33
Weekly Report: what happened at UCBJY last week (0928-1002)?
Weekly Report · 10/05 10:33
UCB SA (0NZT) Receives a Hold from Barclays
TipRanks · 10/02 06:25
Weekly Report: what happened at UCBJY last week (0921-0925)?
Weekly Report · 09/28 10:27
Weekly Report: what happened at UCBJY last week (0914-0918)?
Weekly Report · 09/21 10:27
Barclays Sticks to Its Hold Rating for UCB SA (0NZT)
TipRanks · 09/18 06:16
Weekly Report: what happened at UCBJY last week (0907-0911)?
Weekly Report · 09/14 10:33
Barclays Remains a Hold on UCB SA (0NZT)
TipRanks · 09/08 06:55
Weekly Report: what happened at UCBJY last week (0831-0904)?
Weekly Report · 09/07 10:26
Trump unveils new drug-pricing accords with CSL, Astellas, and other biotech drugmakers
Seeking Alpha · 09/01 04:10
Weekly Report: what happened at UCBJY last week (0824-0828)?
Weekly Report · 08/31 10:34
Weekly Report: what happened at UCBJY last week (0817-0821)?
Weekly Report · 08/24 10:35
Weekly Report: what happened at UCBJY last week (0810-0814)?
Weekly Report · 08/17 10:36
More
Webull provides a variety of real-time UCBJY stock news. You can receive the latest news about Ucb S A through multiple platforms. This information may help you make smarter investment decisions.
About UCBJY
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.